The pending patent covers systemic use of the drug, PH-12, for photodynamic treatment of cancer, skin diseases, and other tissue disorders using visible light activation.
Craig Dees, CEO of Provectus, said: “While we remain focused on clinical development of our lead therapeutic products, PV-10 for cancer and PH-10 for dermatology, this new patent will further solidify an important longer-term opportunity in our development pipeline. It is likely to be some time before we commence clinical testing of PH-12, but given the large potential value in markets worldwide, protection of this new technology enhances value for our shareholders now.”